Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Average Recommendation of "Reduce" by Brokerages

Key Points

• Integra LifeSciences Holdings Corporation has received an average analyst recommendation of "Reduce", with ratings of four sell, three hold, and two buy from the nine analysts covering the stock.
• The average 12-month price target for the stock is $18.63, with several analysts recently decreasing their price objectives, with Wells Fargo setting a target of $13.00.
• Despite a slight increase in Q2 earnings per share, Integra LifeSciences reported a negative net margin of 30.87% and a revenue decline of 0.6% compared to the previous year.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) have been given an average rating of "Reduce" by the nine ratings firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $18.6250.

IART has been the topic of a number of research reports. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. JMP Securities dropped their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. JPMorgan Chase & Co. cut their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Finally, Wells Fargo & Company lowered their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th.

Integra LifeSciences Stock Up 1.4%

Shares of IART stock traded up $0.17 during trading hours on Friday, hitting $12.73. 1,485,006 shares of the company were exchanged, compared to its average volume of 1,214,546. The business's 50-day simple moving average is $12.60 and its two-hundred day simple moving average is $17.51. Integra LifeSciences has a one year low of $11.06 and a one year high of $27.13. The stock has a market capitalization of $991.79 million, a price-to-earnings ratio of -1.95, a P/E/G ratio of 0.71 and a beta of 1.16. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. The business had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%. The business's revenue was down .6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.63 earnings per share. Sell-side analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quadrant Capital Group LLC boosted its position in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in Integra LifeSciences by 205.9% during the second quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock worth $38,000 after acquiring an additional 2,108 shares in the last quarter. Sterling Capital Management LLC increased its holdings in shares of Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after buying an additional 1,931 shares in the last quarter. AlphaQuest LLC acquired a new position in Integra LifeSciences in the second quarter worth $73,000. Finally, CWM LLC raised its stake in shares of Integra LifeSciences by 32.6% in the second quarter. CWM LLC now owns 8,834 shares of the life sciences company's stock worth $108,000 after acquiring an additional 2,170 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.